2m 2m 2m 2m 2m 2m 2m
SERES THERAPEUTI (MCRB)
NASDAQ
$7.23+$0.06 (+0.84%)
Price as of Jun 03, 2026 7:25 PM EDT- $70.9MMarket Cap
- 0.56%1-Year Change
- BiotechnologyIndustry
SERES THERAPEUTI (MCRB)
$7.23+$0.06 (+0.84%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 789,000 N/A | 0 -100.00% | 126.3M +1,672.24% | 7.1M -95.08% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 789,000 N/A | 0 -100.00% | 126.3M +1,672.24% | 7.1M -95.08% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | 37.4M N/A | N/A N/A | |
Research and Development Expense | -49.1M -24.06% | -64.6M -55.71% | -145.9M -15.65% | -172.9M +21.87% | |
Depreciation and Amortization Expense | 4.1M -24.41% | 5.5M -12.41% | 6.2M -5.82% | 6.6M +11.47% | |
Total Operating Expenses | 94.8M -21.89% | 121.3M -48.22% | 234.3M -7.61% | 253.6M +21.10% | |
Operating Profit | -94.0M -22.54% | -121.3M +12.35% | -108.0M -56.19% | -246.5M +282.20% | |
Interest Income | 2.2M -43.86% | 4.0M -45.66% | 7.3M +138.75% | 3.1M +6.55% | |
Interest Expense | 0 N/A | 0 +100.00% | -13.2M +118.87% | -6.0M +106.87% | |
Interest Income and Expense and Net | 2.2M -43.86% | 4.0M +167.52% | -5.9M +98.35% | -3.0M +7,305.00% | |
Total Nonoperating Income and Expense | 99.7M +2,336.69% | -4.5M -22.38% | -5.7M +56.56% | -3.7M +237.97% | |
Income before Taxes | -94.0M -22.54% | -121.3M +12.35% | -108.0M -56.19% | -246.5M +282.20% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 5.7M +4,088.24% | 136,000 +100.12% | -113.7M -54.54% | -250.2M +281.46% | |
Net Income from Continuing Operations Applicable to Common | 5.7M +104.53% | -125.8M +10.59% | -113.7M -54.54% | -250.2M +281.46% | |
Basic EPS and Net Income | 0.64 N/A | 0.00 +100.00% | -0.89 -61.47% | -2.31 +220.83% | |
Diluted EPS and Net Income | 0.64 N/A | 0.00 +100.00% | -0.89 -61.47% | -2.31 +220.83% | |
Basic Weighted Average Shares | 8.9M -94.30% | 155.4M +21.40% | 128.0M +18.44% | 108.1M +17.86% | |
Diluted Weighted Average Shares | 8.9M -94.29% | 155.4M +21.40% | 128.0M +18.44% | 108.1M +17.86% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 45.8M +48.62% | 30.8M -75.94% | 128.0M -21.51% | 163.0M -9.43% | |
Short-Term Investments | N/A N/A | N/A N/A | 0 -100.00% | 18.3M -83.46% | |
Cash and Cash Equivalents and Short-Term Investments | 45.8M +48.62% | 30.8M -75.94% | 128.0M -29.43% | 181.3M -37.62% | |
Total Current Assets | 49.4M +27.67% | 38.7M -77.95% | 175.4M -9.94% | 194.8M -35.85% | |
Accumulated Depreciation | 56.6M +6.42% | 53.2M +4.02% | 51.1M +13.54% | 45.0M +11.85% | |
Property and Plant and Equipment and Net | 7.6M -33.80% | 11.5M -48.64% | 22.5M -2.30% | 23.0M +28.14% | |
Total Long-Term Assets | 31,000 0.00% | 31,000 -99.93% | 41.4M +295.16% | 10.5M +101.68% | |
Total Assets | 138.2M -1.16% | 139.8M -61.01% | 358.6M +2.81% | 348.8M -1.71% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 456,000 +0.44% | |
Total Current Liabilities | 19.3M -53.13% | 41.2M -58.22% | 98.7M +15.26% | 85.6M +4.06% | |
Total Long-Term Debt | N/A N/A | 0 -100.00% | 101.5M +100.72% | 50.6M +105.30% | |
Total Long-Term Liabilities | 2.1M +13.00% | 1.8M +12.90% | 1.6M +12.90% | 1.4M -87.46% | |
Total Liabilities | 94.0M -25.43% | 126.0M -68.76% | 403.5M +19.37% | 338.0M +51.33% | |
Retained Earnings | -972.4M -0.58% | -978.1M -0.01% | -978.2M +13.15% | -864.5M +40.72% | |
Total Stockholders Equity | 44.2M +220.79% | 13.8M +130.73% | -44.9M -515.99% | 10.8M -91.80% | |
Total Shares Outstanding | 9.6M -94.48% | 173.0M +28.11% | 135.0M +7.84% | 125.2M +36.27% | |
Cash Flow | |||||
Cash from Operating Activities | 1.1M +100.75% | -148.6M +26.63% | -117.4M -48.71% | -228.8M -3,521.29% | |
Capital Expenditures | 252,000 -33.68% | 380,000 -95.24% | 8.0M -18.80% | 9.8M +2.67% | |
Cash from Investing Activities | -42,000 -100.03% | 142.3M +1,244.67% | 10.6M -87.16% | 82.4M +28.62% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 13.9M +115.38% | -90.4M -226.03% | 71.7M -44.67% | 129.6M +10,901.87% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -11,910.14% N/A | N/A N/A | -85.48% -97.53% | -3,458.05% +7,670.85% | |
Return on Assets | 4.10% +7,405.13% | 0.05% +100.17% | -32.15% -54.78% | -71.10% +278.30% | |
Return on Equity | 19.64% +2,343.63% | -0.88% -100.13% | 667.53% +289.85% | -351.62% +721.04% | |
Revenue Growth | N/A N/A | -100.00% -105.98% | 1,672.24% +1,858.74% | -95.08% -128.27% | |
Current Ratio | 2.56 +172.37% | 0.94 -47.23% | 1.78 -21.86% | 2.28 -38.36% | |
Cash Ratio | 2.37 +217.08% | 0.75 -42.41% | 1.30 -31.90% | 1.90 -12.96% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | -2.26 -147.82% | 4.73 +2,381.13% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.28 +93.44% | 0.15 +107.07% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow